natgillin/translations-raw huggingface dataset:
Response data are shown in Table 2.
Podatke o odzivnosti kaže preglednica 2.
Do not take Imatinib Teva - if you are allergic to imatinib or any of the other ingredients of this medicine (listed in section 6).
Ne jemljite zdravila Imatinib Teva če ste alergični na imatinib ali katero koli sestavino tega zdravila (navedeno v poglavju
A confirmed haematological response was achieved in 71.5% of patients (Table 3).
Potrjeni hematološki odziv je bil dosežen pri 71,5 % bolnikov (preglednica 3).
235 adult patients with accelerated phase disease were enrolled.
Pospešena faza Vključili so 235 odraslih bolnikov s pospešeno fazo bolezni.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription (such as paracetamol) and including herbal medicines (such as St. John's Wort).
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, tudi če ste ga dobili brez recepta (na primer paracetamol), vključno z zdravili rastlinskega izvora (na primer šentjanževka).
Thrombosis/embolism*
tromboza/embolija*
Chronic phase, Interferon failure
Kronična faza, neuspeh z interferonom
Study 0109 40.5-month data Accelerated phase (n=235)
Študija 0109 podatki pri 40,5 meseca pospešena faza (n = 235)
Ki values in human liver microsomes were 27, 7.5 and 7.9 µmol/l, respectively.
Vrednosti Ki v mikrosomih človeških jeter so bile 27; 7,5 oziroma 7,9 μmol/l.
Your doctor will discuss with you the possible risks of taking Imatinib Teva during pregnancy.
Zdravnik se bo pogovoril z vami o možnih nevarnostih jemanja zdravila Imatinib Teva v nosečnosti.
While you are taking Imatinib Teva your doctor will regularly check whether the medicine is working.
Med jemanjem zdravila Imatinib Teva bo zdravnik redno spremljal, ali zdravilo deluje.
Some children and adolescents taking Imatinib Teva may have slower than normal growth.
Pri nekaterih otrocih in mladostnikih, ki jemljejo zdravilo Imatinib Teva, je lahko rast počasnejša od normalne.
Hepatitis B reactivation
reaktivacija hepatitisa B
The content of the capsule is white to light yellow granulated powder.
Vsebina kapsule je bel do svetlo rumen prašek.
The yearly rates of progression of any type for imatinib also decreased over time.
Tudi letne stopnje kakršnegakoli napredovanja bolezni za imatinib so se sčasoma zmanjševale.
After 42 months of follow-up, 11 patients experienced a confirmed loss (within 4 weeks) of their cytogenetic response.
Po 42 mesecih spremljanja je bila potrjena izguba (v 4 tednih) citogenetičnega odziva pri 11 bolnikih.
260 patients with myeloid blast crisis were enrolled.
Vključili so 260 bolnikov z mieloidno blastno krizo.
Imatinib Teva can reduce the number of white blood cells, so you might get infections more easily.
Zdravilo Imatinib Teva vam lahko zmanjša število belih krvnih celic, zato lahko laže pride do okužbe,
Mean absolute bioavailability for imatinib is 98%.
Povprečna absolutna biološka uporabnost imatiniba je 98 %.
There were 59% males and 41% females; 89.9% caucasian and 4.7% black patients.
Moških je bilo 59 %, žensk pa 41 %; 89,9 % je bilo belcev, 4,7 % pa črncev.
Imatinib pharmacokinetics has not been specifically studied in the elderly.
Farmakokinetike imatiniba pri starejših niso posebej proučili.
Median age was 51 years (range 18-70 years), with 21.9% of patients ≥ 60 years of age.
Povprečna starost je bila 51 let (razpon 18-70 let), 21,9 %
12 Gy in 8 fractions for all patients that are CNS1 and CNS2 at diagnosis
12 Gy v 8 frakcijah za vse bolnike, ki imajo ob postavitvi diagnoze CNS1 in CNS2
Investigations Very common
Preiskave zelo pogosti:
• Blood clots in small blood vessels (thrombotic microangiopathy).
• krvni strdki v majhnih krvnih žilah (trombotična mikroangiopatija).
Major response at 12 months (%)
pomemben odziv pri 12 mesecih (%)
Your doctor has prescribed Imatinib Teva because you suffer from a serious condition.
Zdravnik vam je predpisal zdravilo Imatinib Teva, ker imate resno bolezen.
Imatinib should not be used during pregnancy unless clearly necessary.
Imatinib ne smete uporabljati pri nosečnicah, razen če je nujno potrebno.
The safety and efficacy of imatinib in children with MDS/MPD, DFSP and HES/CEL aged less than 18 years of age have not been established in clinical trials.
Varnost in učinkovitost imatiniba pri otrocih, ki imajo MDS/MPD, DFSP in HES/CEL in so stari manj kot 18 let, nista bili dokazani v kliničnih preskušanjih.
The suspension should be administered immediately after complete disintegration of the tablet(s).
Suspenzijo je treba zaužiti takoj, ko tableta (tablete) popolnoma razpade (razpadejo).
Table 2 Response in newly diagnosed CML Study (84-month data)
Preglednica 2 Odziv v študiji na novo diagnosticirane KML (podatki pri 84 mesecih)
Because of known increased risks of bleeding in conjunction with the use of imatinib (e.g. haemorrhage), patients who require anticoagulation should receive low-molecular-weight or standard heparin, instead of coumarin derivatives such as warfarin.
Zaradi znanega povečanega tveganja za krvavitve v povezavi z uporabo imatiniba (na primer hemoragija), naj bolniki, pri katerih je potrebna antikoagulantna terapija, dobivajo nizkomolekularni ali standardni heparin namesto kumarinskih derivatov, kot je varfarin.
Major response at 24 months (%)
pomemben odziv pri 24 mesecih (%)
Acute respiratory failure11*, interstitial lung disease*
akutna respiratorna odpoved11*, intersticijska pljučna bolezen*
Imatinib Teva will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours.
Zdravilo Imatinib Teva vam lahko predpiše samo zdravnik, ki ima izkušnje z zdravili za zdravljenje krvnih rakov ali solidnih tumorjev.
Studies in two breast-feeding women revealed that both imatinib and its active metabolite can be distributed into human milk.
Študiji pri dveh doječih materah sta pokazali, da se tako imatinib kot njegov aktivni presnovek pri človeku lahko izločata v materino mleko.
- Imatinib Teva is not recommended during pregnancy unless clearly necessary as it may harm your baby.
Uporaba zdravila Imatinib Teva v nosečnosti ni priporočena, če to ni nujno potrebno, saj lahko škoduje vašemu otroku.
There is no experience in children with CML below 2 years of age and with Ph+ALL below 1 year of age (see section 5.1).
Izkušenj pri otrocih s KML, mlajših od 2 let, in pri otrocih s Ph+ALL, mlajših od 1 leta, ni (glejte poglavje 5.1).
Constitutive activation of the PDGF receptor or the Abl protein tyrosine kinases as a consequence of fusion to diverse partner proteins or constitutive production of PDGF have been implicated in the pathogenesis of MDS/MPD, HES/CEL and DFSP.
Konstitutivna aktivacija receptorja za PGDF ali Abl protein-tirozin-kinaze kot posledica združitve različnih sodelujočih proteinov ali konstitutivna tvorba PDGF sta vpleteni v patogenezo MDS/MPD, HES/CEL in DFSP.
- If you are being treated for DFSP:
Če se zdravite zaradi DFSP:
* These types of reactions have been reported mainly from post-marketing experience with imatinib.
* O teh vrstah neželenih učinkov so poročali večinoma v okviru izkušenj v obdobju trženja zdravila z zdravilom Imatinib.
ANC ≥ 1 x 10
dokler ni ANC ≥ 1 x 10
- If you are being treated for MDS/MPD:
Če se zdravite zaradi MDS/MPD:
Cerebral oedema*
možganski edem*
The degree of cytogenetic response and molecular response had a clear effect on long-term outcomes in patients on imatinib.
Stopnja citogenetičnega in molekularnega odziva ima nedvomen učinek na dolgoročni izid pri bolnikih, zdravljenih z imatinibom.
Merckle GmbH Graf-Arco-Str. 3, 89079 Ulm Germany
Merckle GmbH Graf-Arco-Str. 3, 89079 Ulm
The primary efficacy variable of the study was the rate of major cytogenetic response (complete plus partial response, 0 to 35% Ph+ metaphases in the bone marrow).
Primarna učinkovitostna spremenljivka študije je bila stopnja pomembnega citogenetičnega odziva (popolni plus delni odziv, 0 do 35 % Ph+ metafaz v kostnem mozgu).
Imatinib Teva inhibits the growth of these cells in a certain subtype of these diseases.
Zdravilo Imatinib Teva zavira rast teh celic pri določenih podskupinah teh bolezni.
This clinical effect was associated with a higher reduction in bcr-abl transcripts in the imatinib-treated patients than in the chemotherapy arm after 2 weeks of therapy (p=0.02).
Ta klinični učinek je bil povezan z večjim zmanjšanjem količine transkriptov bcr abl pri bolnikih, zdravljenih z imatinibom, kot pri skupini, zdravljeni s kemoterapijo po 2 tednih zdravljenja (p=0,02).
PLIVA Croatia Ltd. Prilaz baruna Filipovica 25 10000 Zagreb Croatia
Prilaz baruna Filipovica 25 10000 Zagreb Hrvaška
21 patients were treated with imatinib 400 mg daily, while the other 3 patients received lower doses.
21 bolnikov je prejemalo imatinib v odmerku 400 mg na dan, drugi 3 bolniki pa so prejemali manjše odmerke.
ANC = absolute neutrophil count a occurring at least after one month of treatment
ANC = absolutno število nevtrofilcev (absolute neutrophil count) a do katere pride po najmanj 1 mesecu zdravljenja
Experience with imatinib in this indication is very limited and is based on haematological and cytogenetic response rates.
Za to indikacijo je izkušenj z imatinibom zelo malo in temeljijo na hematološki in citogenetični odzivnosti.
The length of the capsule is from 23.0 mm to 23.6 mm and the width is 8.53 mm.
Dolžina kapsule znaša od 23,0 mm do 23,6 mm in je široka 8,53 mm.
• Sudden swelling and redness of the skin (signs of a skin infection called cellulitis).
• nenadna oteklina in pordelost kože (znaki kožne okužbe z imenom flegmona (celulitis)),
In contrast, there were 165 (29.8%) events in the IFN+Ara-C arm, of which 130 occurred during first-line treatment with IFN+Ara-C.
Za razliko od tega je bilo v kraku z IFN+AraC 165 (29,8 %) dogodkov, od tega se jih je 130 zgodilo v času zdravljenja z IFN+Ara-C kot zdravilom prvega izbora.
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the
vendar pa je pojavljanje citopenij tudi nedvomno odvisno od stadija bolezni.
The median duration of second-line treatment with imatinib was 64 months.
Mediano trajanje zdravljenja z imatinibom kot zdravilom drugega izbora je bilo 64 mesecev.
Neoplasm benign, malignant and unspecified (including cysts and polyps) Rare
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi)
If this applies to you, tell your doctor without taking Imatinib Teva.
Če to velja za vas, povejte zdravniku in ne jemljite zdravila Imatinib Teva.
(0.5 h), days 7, 8, 14, 15;
(0,5 ure), 7., 8., 14., 15. dan;
In clinical trials, there was an increased incidence of these events in the elderly and those with a prior history of cardiac disease.
V kliničnih preskušanjih so bili ti učinki pogostejši pri starejših in pri bolnikih z anamnezo bolezni srca.
Study 0102 38-month data Myeloid blast crisis (n=260)
Študija 0102 podatki pri 38 mesecih mieloidna blastna kriza (n = 260)
Table 5 Chemotherapy regimen used in combination with imatinib in study I2301
Preglednica 5 Kemoterapevtske sheme, uporabljene v kombinaciji z imatinibom v študiji I2301
• Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis.
• odraslih in pediatričnih bolnikov s Ph+ KML v kronični fazi po neuspelem zdravljenju z interferonom alfa, ali v pospešeni fazi ali blastni krizi;
FIP1L1-PDGFRα-positive in other 3 published reports.
FIP1L1-PDGFRα pozitivni so bili še štirje bolniki s HES, ki so jih opisovali v drugih 3 objavljenih poročilih.
C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Spain
C/C, n. 4, Poligono Industrial Malpica, 50016 Zaragoza Španija
Major cytogenetic response, haematological response, molecular response (evaluation of minimal residual disease), time to accelerated phase or blast crisis and survival are main secondary endpoints.
Pomemben citogenetični odziv, hematološki odziv, molekularni odziv (ovrednotenje minimalne rezidualne bolezni), čas do pospešene faze ali blastne krize in preživetje so poglavitni sekundarni cilji opazovanja.
20 out of the 50 (40%) patients in cohort 5 received haematopoietic stem cell transplant.
od 50 bolnikom (40 %) v 5. kohorti so presadili krvotvorne matične celice.
The length of the capsule is from 19.1 mm to 19.7 mm and the width is 6.91 mm. Imatinib Teva 400 mg hard capsules
Dolžina kapsule znaša od 19,1 mm do 19,7 mm in je široka 6,91 mm. Imatinib Teva 400 mg trde kapsule
• The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
• zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
In the event of overdose the patient should be observed and appropriate symptomatic treatment given.
V primeru prevelikega odmerjanja je treba bolnika opazovati in mu nuditi ustrezno simptomatsko zdravljenje.
A major response combines both complete and partial responses: complete (0% Ph+ metaphases), partial (1-35%)
Pomemben odziv združuje tako popolne kot delne odzive: popoln (0 % Ph+ metafaz), delen (1
(1 h), days 26, 46;
(1 ura), 26., 46. dan;
For the patients treated at 600 mg, the current estimates for median progression-free-survival and overall survival were 22.9 and 42.5 months, respectively.
Za bolnike, zdravljene s 600 mg, je trenutna ocena medianega preživetja brez napredovanja bolezni in preživetja nasploh 22,9 oziroma 42,5 meseca.
The effect of imatinib treatment on survival in chronic phase, newly diagnosed CML has been further examined in a retrospective analysis of the above reported imatinib data with the primary data from another Phase III study using IFN+Ara-C (n=325) in an identical regimen.
Vpliv zdravljenja z imatinibom na preživetje v kronični fazi pri novo diagnosticirani KML so nadalje preiskovali z retrospektivno analizo zgoraj opisanih podatkov o imatinibu skupaj s prvotnimi podatki druge študije faze III, v kateri so uporabljali IFN+Ara-C s povsem enakim režimom zdravljenja (n = 325).
If you forget to take Imatinib Teva - If you forget a dose, take it as soon as you remember.
Če ste pozabili vzeti zdravilo Imatinib Teva - Če pozabite vzeti odmerek, ga vzemite takoj, ko se spomnite.
When needed, discontinuation of Imatinib Teva treatment may be considered.
Če je treba, velja razmisliti o prekinitvi zdravljenja z zdravilom Imatinib Teva.
Ara-C: cytosine arabinoside; CP: cyclophosphamide; DEX: dexamethasone; MTX: methotrexate; 6MP: 6-mercaptopurine VM26: Teniposide; VCR: vincristine; IDA: idarubicine; i.v.
Ara-C: citozin arabinozid; CP: ciklofosfamid; DEX: deksametazon; MTX: metotreksat; 6-MP: 6merkaptopurin; VM26: tenipozid; VCR: vinkristin; IDA: idarubicin; i.v.
In this retrospective analysis, the superiority of imatinib over IFN+Ara-C in overall survival was demonstrated (p<0.001); within 42 months, 47 (8.5%) imatinib patients and 63 (19.4%) IFN+Ara-C patients had died.
V tej retrospektivni analizi se je z vidika celotnega preživetja imatinib izkazalo za boljše od IFN+Ara-C (p < 0,001): v 42 mesecih je umrlo 47 (8,5 %) bolnikov z imatinibom in 63 (19,4 %) bolnikov z IFN+Ara-C.
Accelerated phase
Predhodna faza
When and how to take Imatinib Teva - Take Imatinib Teva with a meal.
Kdaj in kako jemati zdravilo Imatinib Teva Zdravilo Imatinib Teva vzemite z obrokom hrane.
Complete (Confirmed3) [95% CI]
popoln (potrjen3) [95 %-ni interval zaupanja] delen
For adult patients with relapsed or refractory Ph+ALL imatinib monotherapy at 600 mg/day is safe, effective and can be given until disease progression occurs.
Za odrasle bolnike z relapsom ali neodzivno Ph+ ALL je imatinib kot monoterapija v odmerku 600 mg/dan varen in učinkovit ter ga lahko prejemajo dokler ne pride do napredovanja bolezni.
Major molecular response criteria: in the peripheral blood reduction of ≥ 3 logarithms in the amount of Bcr-Abl transcripts (measured by real-time quantitative reverse transcriptase PCR assay) over a standardised baseline.
Kriteriji pomembnega molekularnega odziva: zmanjšanje količine Bcr-Abl transkriptov v periferni krvi za ≥ 3 logaritme (merjeno s kvantitativno PCR določitvijo reverzne transkriptaze v realnem času) glede na standardizirane izhodiščne vrednosti.
Importantly, 27.7% of patients also achieved a major cytogenetic response, which was complete in 20.4% (confirmed 16%) of patients.
Pri tem je pomembno, da je 27,7 % bolnikov doseglo tudi pomemben citogenetični odziv, ki je bil pri 20,4 %
One large, open-label, multicentre, international randomised phase III study has been conducted in patients with newly diagnosed Ph+ CML.
Eno veliko odprto, multicentrično, mednarodno randomizirano študijo tretje faze so opravili pri bolnikih z na novo diagnosticirano Ph+ KML.
- Women who might become pregnant are advised to use effective contraception during treatment.
Ženskam, ki bi lahko zanosile, med zdravljenjem priporočamo uporabo učinkovite kontracepcijske metode.
For patients with reduction in Bcr-Abl transcripts of at least 3 logarithms at 12 months, the probability of remaining free from progression to accelerated phase/blast crisis was 99% at 84 months.
Pri bolnikih z zmanjšanjem števila transkriptov Bcr-Abl za vsaj 3 logaritme pri 12 mesecih je bila verjetnost, da bolezen ne napreduje v pospešeno fazo/blastno krizo, po 84 mesecih 99 %.
Of these 11 patients, 4 patients escalated up to 800 mg daily, 2 of whom regained a cytogenetic response (1 partial and 1 complete, the latter also achieving a molecular response), while of the 7 patients who did not escalate the dose, only one regained a complete cytogenetic response.
Od teh 11 bolnikov so 4 bolnikom zvečali odmerek na 800 mg na dan, od njih sta 2 spet dobila citogenetični odziv (1 delnega in 1 popolnega, le-ta je dosegel tudi molekularni odziv), medtem ko je od 7 bolnikov, pri katerih odmerka niso zvečali, le eden spet dobil popolni citogenetični odziv.
Imatinib Teva inhibits the growth of these cells.
Zdravilo Imatinib Teva zavira rast teh celic.
The median duration of therapy in the published literature ranged between 4 weeks and more than 20 months.
Mediano trajanje zdravljenja v objavljeni literaturi se je gibalo od 4 tednov do več kot
Check whether cytopenia is related to leukaemia (marrow aspirate or biopsy).
1.Preverite, ali je citopenija povezana z levkemijo (aspirat ali biopsija kostnega mozga).
If anti-ADAMTS13-antibody is elevated in conjunction with low ADAMTS13 activity, treatment with Imatinib Teva should not be resumed.
primeru, da je koncentracija protiteles proti ADAMTS13 zvišana, aktivnost ADAMTS13 pa nizka, se zdravljenja z zdravilom Imatinib Teva ne sme nadaljevati.
However, since the effects of low-dose exposure of the infant to imatinib are unknown, women taking imatinib should not breastfeed.
Vendar učinki izpostavljenosti dojenčka majhnim odmerkom imatiniba niso znani, zato ženske, ki jemljejo imatinib ne smejo dojiti.
days 1-3;
1.-3. dan;
Not applicable Not applicable
se smiselno ne uporablja se smiselno ne uporablja
Lymphoid blast crisis
Limfoidna blastna kriza
The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1).
Izkušnje z uporabo imatiniba pri bolnikih z MDS/MPD v povezavi s preureditvijo genov za PDGFR so zelo omejene (glejte poglavje 5.1).
The active substance imatinib demonstrates an environmental risk for sediment organisms.
Zdravilna učinkovina imatinib predstavlja okoljsko tveganje za organizme v sedimentih.
Imatinib inhibits signalling and proliferation of cells driven by dysregulated PDGFR and Abl kinase activity.
Imatinib zavira signaliziranje in proliferacijo celic, ki ju povzroča napačno uravnavano delovanje PDGFR in aktivnosti Abl kinaze.
Haematological response1 Complete haematological response (CHR) No evidence of leukaemia (NEL)
Hematološki odziv1 popolni hematološki odziv (CHR) nobenih znakov levkemije (NEL)
The first 77 patients were started at 400 mg, the protocol was subsequently amended to allow higher dosing and the remaining 158 patients were started at 600 mg.
Prvih 77 bolnikov je začelo zdravljenje z odmerkom 400 mg, pozneje je bil protokol dopolnjen, da je omogočil večje odmerjanje in je preostalih 158 bolnikov začelo s 600 mg.
Metabolism of imatinib is mainly hepatic, and only 13% of excretion is through the kidneys.
Hepatotoksičnost Presnova imatiniba poteka predvsem v jetrih in le 13 % se izloča skozi ledvice.
• Eye pain or deterioration in vision, bleeding in the eyes.
• bolečine v očeh ali poslabšanje vida, očesna krvavitev,
• Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.
• odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) in/ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFRα.
Imatinib Teva may do the same to some other medicines.
Zdravilo Imatinib Teva lahko enako vpliva na nekatera druga zdravila.
Do not stop taking Imatinib Teva unless your doctor tells you to.
Ne prenehajte jemati zdravila Imatinib Teva, razen če vam tako naroči zdravnik.
A total of 71 (12.8%) and 85 (15.4%) patients died in the imatinib and IFN+Ara-C groups, respectively.
Skupno je umrlo 71 (12,8 %) bolnikov iz skupine z imatinibom in 85 (15,4 %) iz skupine z IFN+AraC.
Therapy should be initiated by a physician experienced in the treatment of patients with haematological malignancies and malignant sarcomas, as appropriate.
4.2 Odmerjanje in način uporabe Zdravljenje mora začeti zdravnik, izkušen v zdravljenju bolnikov s hematološkimi malignimi boleznimi in malignimi sarkomi, kot je primerno.
Other medicines and Imatinib Teva
Druga zdravila in zdravilo Imatinib Teva
In the juvenile toxicology study, effects upon growth, delay in vaginal opening and preputial separation were observed at approximately 0.3 to 2 times the average paediatric exposure at the highest recommended dose of 340 mg/m2.
V študiji toksičnih učinkov na razvoj mladičev so opažali vpliv na rast ter zakasnjeno odpiranje nožnice in ločevanje prepucija pri izpostavljenosti, ki ustreza približno 0,3 do 2-kratniku izpostavljenosti, do kakršne v povprečju pride pri otrocih, ki prejemajo največji priporočeni odmerek 340 mg/m2.
Imatinib Teva is a medicine containing an active substance called imatinib.
Zdravilo Imatinib Teva je zdravilo, ki vsebuje zdravilno učinkovino z imenom imatinib.
Imatinib at 400 mg twice daily had an inhibitory effect on CYP2D6-mediated metoprolol metabolism, with metoprolol Cmax and AUC being increased by approximately 23% (90%CI [1.16-1.30]).
Imatinib je v odmerku 400 mg dvakrat na dan zaviral presnovo metoprolola s CYP2D6, tako da sta se Cmax in AUC metoprolola povečali za približno 23 % (90 % IZ [1,16-1,30]).
Depression, libido decreased, anxiety
depresija, zmanjšan libido, anksioznost redki:
The more frequent adverse reactions included gastrointestinal haemorrhages, conjunctivitis and elevation of transaminases or bilirubin.
Med pogostejšimi neželenimi reakcijami so bili gastrointestinalne krvavitve, konjunktivitis in zvišanje aminotransferaz ali bilirubina.
These patients received imatinib for a median of 47 months (range 24 days - 60 months).
Ti bolniki so prejemali imatinib mediano 47 mesecev (od 24 dni do 60 mesecev).
In patients with impaired renal function, imatinib plasma exposure seems to be higher than that in patients with normal renal function, probably due to an elevated plasma level of alpha-acid glycoprotein (AGP), an imatinib-binding protein, in these patients.
Kaže, da je pri bolnikih z okvarjenim delovanjem ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih z normalnim delovanjem ledvic, verjetno zato, ker je pri teh bolnikih zvišana vrednost alfa kislega glikoproteina (AGP - alpha-acid glycoprotein) v plazmi, proteina, ki veže imatinib.
These are blood diseases in which some blood cells (named eosinophils) start growing out of control.
To so bolezni krvi, pri katerih se začnejo nenadzorovano razraščati nekatere krvne celice (imenovane eozinofilci).